About Roper Technologies Inc
- Industry: Technology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ropertech.com/
Frequently Asked Questions
What is the 52-week range for ROP?
The 52-week high is $521.28 and the 52-week low is $305.96.
What is the P/E ratio for ROP?
The Price to Earnings (P/E) ratio is 13.99.
What is the dividend yield for ROP?
The indicated annual dividend yield is 0.57%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 12.94%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 30.24%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.41.
Analyst Recommendation Trends
Wall Street analyst consensus for ROP over the last few months:
Latest ROP News
3 European Defensive Stocks Investors Are Watching As Bond Markets Turn Risk Off
Bond markets are throwing out fresh stress signals, with investors racing toward German Bunds and dumping riskier debt across Europe. That kind of flight to safety can punish cyclical stocks and fragile balance sheets, yet it can also shine a harsh but helpful spotlight on sturdier businesses. This article explores 3 Core European Defensive Equities that are closely exposed to this bond shock and explains why their reactions might matter for your portfolio decisions now. The three stocks...
What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?
Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutinib could become the first high efficacy oral BTK inhibitor targeting both relapse control and disability progression in MS. The FDA's priority review for fenebrutinib in relapsing and primary progressive MS...
Roper Technologies' Q3 2026 Earnings: What to Expect
Roper Technologies is expected to release its third-quarter earnings soon, and analysts expect a double-digit percentage rise in its bottom line.
Abhijit Dubey joins Roper Technologies Board of Directors
SARASOTA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that Abhijit Dubey has joined the Company's Board of Directors. Mr. Dubey is Chief Executive Officer and Chief AI Officer of NTT DATA, Inc., a global business and technology services company. He also serves as a Director of NTT DATA Group Corporation, the publicly listed parent company of NTT DATA, Inc. In his current role, Mr. Dubey leads NTT DATA's strategy, growth, and operating performance, as
Roper Technologies schedules third quarter 2026 financial results conference call
SARASOTA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that its financial results for the third quarter of 2026, ended September 30, 2026, will be released before the market opens on Thursday, October 22, 2026. A conference call to discuss these results has been scheduled for 8:00 AM ET on Thursday, October 22, 2026. The call can be accessed via webcast or by dialing +1 800-836-8184 (US/Canada) or +1 646-357-8785, using conference call ID 80101. Webcas
Roche launches newborn screening test for three severe genetic conditions
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD). This launch provides a crucial, ready-to-use solution for private and academic hospital labs, enabling the ea
CTSH or ROP: Which Is the Better Value Stock Right Now?
CTSH vs. ROP: Which Stock Is the Better Value Option?
Best Dividend Aristocrats For October 2026
The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.
Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships
Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and...
4 Dividend Rules That Keep Retirees From Buying a Payout That Gets Cut
A fat dividend yield can signal generosity or a countdown clock, and retirees who chase the wrong one lose twice when the payout finally breaks. Four tests separate the durable payers from the traps before the cut arrives.
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
3 Industrial Stocks You’ve Never Heard of With 25+ Years of Dividend Increases
Most dividend growth watchlists stop at consumer staples brands you already know, but three industrial compounders have quietly raised their payouts every year for over a quarter century while making things most investors never think about.
Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues
Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current...
Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?
Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than...
Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma
Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio’s label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for...
ROP Benefits From Strength in Application Software Unit: Can the Momentum Sustain?
Roper's Application Software segment is powering growth with rising SaaS adoption, recurring revenue strength and GenAI innovation across key businesses.
Illumia Appoints Don Smith to Lead Higher Education Portfolio
SCOTTSDALE, Ariz., September 15, 2026--Illumia, a leading provider of technology solutions that power payments, identity, commerce and foodservice operations across higher education, healthcare and corporate campuses, today announced the appointment of Don Smith to senior vice president & general manager, higher education. Smith will work across product, technology, commercial and customer teams to better connect Illumia’s products and experiences. The goal is to make it easier for colleges and
DAT: Spot van rate falls 20 cents in steepest August pullback on record
PORTLAND, Ore., Sept. 15, 2026 (GLOBE NEWSWIRE) -- National average truckload spot rates fell across all three equipment types in August, posting the steepest July-to-August declines in DAT’s 16-year rate history, according to DAT Freight & Analytics, provider of the industry’s leading load boards and freight analytics. The pullback also moved dry van and refrigerated (“reefer”) spot rates back below contract rates after spot rates exceeded contract rates in June and July. Spot rates post record
These S&P500 stocks that are showing activity before the opening bell on Tuesday.
Pre-market stock analysis of S&P500 stocks on 2026-09-15: top gainers and losers in today's session.
Roper Technologies, Inc. (ROP) Presents at Piper Sandler 5th Annual Growth Frontiers Conference Transcript
Roper Technologies, Inc. (ROP) Piper Sandler 5th Annual Growth Frontiers Conference September 15, 2026 9:30 AM EDTCompany ParticipantsJason Conley -...
Procare Solutions Acquires Playground, Combining Industry Leading Expertise with Innovative, AI-Powered Child Care Technology
Procare Solutions, a leader in AI-enabled child care management software, trusted by more than 40,000 centers nationwide, announced today it has acquired Playground, a modern, all-in-one child care management platform recognized for its intuitive design, top-rated customer support and AI-powered tools, including Camber, the first AI assistant purpose-built for child care.
These S&P500 stocks are moving in today's pre-market session
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
Roper Technologies, Inc. (ROP) Presents at Citi's 2026 Global TMT Conference Transcript
Roper Technologies, Inc. (ROP) Citi's 2026 Global TMT Conference September 10, 2026 8:50 AM EDTCompany ParticipantsJason Conley - Executive VP & CFONeil...
Roper Technologies In Rebound and a Hot Buy Despite Insider Selling
Despite summer insider selling, Roper Technologies shows strong Q2 fundamentals, raised guidance, buybacks, healthy balance sheet, and analyst and institutional support driving its stock rebound.
Roper Technologies to present at Piper Sandler Conference
SARASOTA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Piper Sandler Growth Frontiers Conference on Tuesday, September 15, 2026, at 8:30 AM (Central Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track r
Is Roper Technologies Stock Underperforming the Dow?
Roper Technologies has notably underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Why Roche Holding (SWX:ROP) Is Getting Attention Today
Roche Holding (SWX:ROP) has been back in focus after Treeline Biosciences agreed to a clinical trial collaboration that combines TLN-121 with Roche bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Roche Holding shares trade at CHF357.0, with a 90-day share price return of 10.63% and a year-to-date share price return of 9.68%. The 1-year total shareholder return of 34.18% points to momentum that has built alongside a steady stream of oncology and diagnostics...
Roche (SWX:ROP) Stock Looks Reasonable On Earnings But Mixed On Value
Roche Holding stock has delivered a solid multi year gain, yet the valuation signals are more mixed, which leaves investors weighing a strong price record against a less clear cut verdict on how cheap the shares really are. After a 3 year climb, the stock now screens as neither an obvious bargain nor clearly expensive. Roche Holding has returned about 54.2% over the past 3 years, which puts extra focus on whether that share price performance already reflects most of the good news in the...
Roche Holding (SWX:ROP) Received FDA Clearance For An Alzheimer’s Blood Test
Roche Holding (SWX:ROP) announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas. The partners plan to evaluate advanced immune based treatments aimed at improving options for lymphoma patients. Roche received FDA clearance for its Elecsys pTau217 blood test as the first single biomarker assay to help both rule in and rule out amyloid pathology in Alzheimer’s disease. The Elecsys pTau217 test is intended to support clinicians in earlier...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Joyce Thomas Patrick JR | +78 | - | - |
| 2026-09-15 | ARCHAMBEAU SHELLYE L | +84 | - | - |
| 2026-09-15 | ESTEVES IRENE M | +78 | - | - |
| 2026-07-27 | Stipancich John K | -2,000 | $228.84 | $457,680 |
| 2026-07-27 | Stipancich John K | -2,000 | $379.05 | $758,100 |
| 2026-07-27 | Stipancich John K | +2,000 | $228.84 | $457,680 |
| 2026-07-24 | WALLMAN RICHARD F | -6,434 | $361 | $2,322,674 |
| 2026-05-20 | Thatcher Laura G | +1,191 | - | - |
| 2026-05-20 | Murphy John Francis | +1,191 | - | - |
| 2026-05-20 | Joyce Thomas Patrick JR | +1,191 | - | - |
| 2026-05-20 | JOHNSON ROBERT D | +1,191 | - | - |
| 2026-05-20 | WALLMAN RICHARD F | +1,191 | - | - |
| 2026-05-20 | ARCHAMBEAU SHELLYE L | +1,191 | - | - |
| 2026-05-20 | ESTEVES IRENE M | +1,191 | - | - |
| 2026-05-20 | BRINKLEY AMY WOODS | +1,191 | - | - |
| 2026-03-16 | WALLMAN RICHARD F | +92 | - | - |
| 2026-03-16 | ESTEVES IRENE M | +85 | - | - |
| 2026-03-16 | Joyce Thomas Patrick JR | +85 | - | - |
| 2026-03-16 | ARCHAMBEAU SHELLYE L | +92 | - | - |
| 2026-03-10 | Cross Brandon L | +3,626 | - | - |
| 2026-03-10 | Cross Brandon L | +972 | - | - |
| 2026-03-10 | Cross Brandon L | +230 | - | - |
| 2026-03-10 | Cross Brandon L | -110 | $353.87 | $38,926 |
| 2026-03-10 | Conley Jason | +26,535 | - | - |
| 2026-03-10 | Conley Jason | -3,065 | $353.87 | $1,084,612 |
| 2026-03-10 | Stipancich John K | +24,494 | - | - |
| 2026-03-10 | Stipancich John K | -3,198 | $353.87 | $1,131,676 |
| 2026-03-10 | HUNN LAURENCE NEIL | +67,495 | - | - |
| 2026-03-10 | HUNN LAURENCE NEIL | -12,854 | $353.87 | $4,548,645 |
| 2026-02-06 | Joyce Thomas Patrick JR | +1,400 | $358.46 | $501,844 |
| 2025-12-08 | WALLMAN RICHARD F | -4,000 | - | - |
| 2025-12-01 | Conley Jason | -6,000 | $170.61 | $1,023,660 |
| 2025-12-01 | Conley Jason | -6,000 | $445.565 | $2,673,390 |
| 2025-12-01 | Conley Jason | +6,000 | $170.61 | $1,023,660 |
| 2025-11-12 | HUNN LAURENCE NEIL | +2,000 | $451.575 | $903,150 |
| 2025-11-12 | HUNN LAURENCE NEIL | +8,000 | $452.395 | $3,619,160 |
| 2025-11-12 | BRINKLEY AMY WOODS | +1,200 | $450.713 | $540,856 |
| 2025-11-11 | HUNN LAURENCE NEIL | -30,000 | $186.75 | $5,602,500 |
| 2025-11-11 | HUNN LAURENCE NEIL | -361 | $448.3976 | $161,872 |
| 2025-11-11 | HUNN LAURENCE NEIL | -479 | $446.6082 | $213,925 |
| 2025-11-11 | HUNN LAURENCE NEIL | -1,725 | $445.5662 | $768,602 |
| 2025-11-11 | HUNN LAURENCE NEIL | -2,839 | $444.7539 | $1,262,656 |
| 2025-11-11 | HUNN LAURENCE NEIL | -9,055 | $443.6762 | $4,017,488 |
| 2025-11-11 | HUNN LAURENCE NEIL | -14,143 | $442.958 | $6,264,755 |
| 2025-11-11 | HUNN LAURENCE NEIL | -1,398 | $441.973 | $617,878 |
| 2025-11-11 | HUNN LAURENCE NEIL | +30,000 | $186.75 | $5,602,500 |